9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment of adults with excessive daytime sleepiness caused by obstructive sleep apnoea.

Solriamfetol hydrochloride is not recommended to improve wakefulness and reduce excessive daytime sleepiness in adults with obstructive sleep apnoea whose sleepiness has not been satisfactorily treated by primary obstructive sleep apnoea therapy, such as continuous positive airway pressure.

Read NICE final appraisal determination for solriamfetol hydrochloride